FDA Delays Action On MedImmune's Rezield Despite Negative Panel Vote
This article was originally published in Pharmaceutical Approvals Monthly
In a surprise move, FDA has delayed action on MedImmune's Rezield (motavizumab), its second-generation preventive treatment for respiratory syncytial virus, even though the agency already has a vote against approval from an overwhelmingly negative advisory committee review three weeks earlier
You may also be interested in...
Alongside FDA's concerns about possible bias in the Phase III clinical trials of Rezield (motavizumab), MedImmune faces an accusation of data suppression from a former employee who alleges he was fired for bringing up problems with sample screening
Members of FDA's Antiviral Drugs Advisory Committee say that MedImmune's RSV drug Rezield (motavizumab) doesn't pass the risk-benefit test for healthier patients, but it might for sicker patients.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011